Daiichi Sankyo buys solid tumour ADC from Glycotope for $132.5m Daiichi Sankyo has finalised the acquisition of intellectual ...

Drugmaker Daiichi Sankyo has risen the most in five months after its novel breast cancer treatment won U.S. approval, a ...

Approval is based on results from the TROPION-Breast01 Phase III trial, in which Datroway demonstrated a significant reduction in the risk of disease progression or death in patients with previously ...

The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of ...

Daiichi Sankyo has finalised the acquisition of intellectual property rights for gatipotuzumab, an anti-tumour-associated mucin-1 (TA-MUC1) antibody, from Glycotope for $132.5m. The gatipotuzumab ...

Daiichi Sankyo Company, Ltd, an innovative global healthcare company, announced that it will pay Glycotope $132.5 million to acquire intellectual property rights of the antitumor-associated mucin-1 ...

BioMed X, an independent biomedical research institute based in Heidelberg, Germany, announced today the launch of a new ...

The broader Topix index settled 1.19 percent higher at 2,711.27. Automakers led the surge, with Honda Motor rising 1.4 percent while Toyota Motor and Subaru both gained around 3 percent.

TOKYO & BASKING RIDGE, N.J., January 13, 2025--Daiichi Sankyo Company, Ltd (TSE: 4568) announced today that it will pay Glycotope $132.5 million to acquire intellectual property rights of the ...

Earnings Per Share (TTM) A company's net income for the trailing twelve month period expressed as a dollar amount per fully diluted shares outstanding. Market Capitalization Reflects the total ...

Earnings Per Share (TTM) A company's net income for the trailing twelve month period expressed as a dollar amount per fully diluted shares outstanding. Market Capitalization Reflects the total ...